tradingkey.logo
tradingkey.logo
Search

ENDRA Life Sciences Inc

NDRA
Add to Watchlist
4.610USD
+0.280+6.47%
Close 07-31 16:00ETQuotes delayed by 15 min
5.42MMarket Cap
LossP/E TTM

ENDRA Life Sciences Inc

4.610
+0.280+6.47%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+6.47%

5 Days

-5.14%

1 Month

-13.51%

6 Months

+21.32%

Year to Date

+1.77%

1 Year

-12.69%

Key Figures
4.410Open
4.700High
18.67KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.59%Turnover Ratio
4.330Prev. Close
4.250Low
65.80KTurnover
LossP/E Static
2.40P/B
0.00%Div Yield TTM
-220.99%ROA
11.96052wk High
1.50Volume Ratio
-11.51MNet Profit
1.18MShares
-8.1638EPS TTM
-0.05Beta
-412.60%ROE
2.96052wk Low
10.39%Amplitude
--Gross Margin
5.42MMarket Cap
-1.30Reward/Risk
6.37%Risk Rate

Key Insights

ENDRA Life Sciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ENDRA Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
95 / 385
Overall Ranking
177 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

ENDRA Life Sciences Inc Highlights

StrengthsRisks
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Undervalued
The company’s latest PE is -0.58, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 218.33K shares, increasing 38.70% quarter-over-quarter.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
25.000
Target Price
+461.80%
Upside Space

ENDRA Life Sciences Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 1 analysts
Buy
Current Rating
25.000
Target Price
+461.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
ENDRA Life Sciences Inc
NDRA
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(3)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.191
Sell
RSI(14)
46.105
Neutral
STOCH(KDJ)(9,3,3)
17.837
Neutral
ATR(14)
0.466
Low Volatility
CCI(14)
-88.511
Neutral
Williams %R
72.892
Sell
TRIX(12,20)
-0.230
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
4.544
Buy
MA10
4.873
Sell
MA20
5.062
Sell
MA50
5.018
Sell
MA100
4.854
Sell
MA200
4.876
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ENDRA Life Sciences Inc Info

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Ticker SymbolNDRA
CompanyENDRA Life Sciences Inc
CEOTokman (Alexander Y)
Websitehttps://www.endrainc.com/

Shareholders

Shareholders
Shareholders
Proportion
ATW Partners LLC
9.35%
Lipman (John Carter)
6.13%
DiGiandomenico (Anthony)
5.71%
Altium Capital Management LP
4.18%
Jacroux (Richard)
2.70%
Other
71.92%

FAQs

What is the current price of ENDRA Life Sciences Inc (NDRA)?

The current price of ENDRA Life Sciences Inc (NDRA) is 4.61.

What is the symbol of ENDRA Life Sciences Inc?

The ticker symbol of ENDRA Life Sciences Inc is NDRA.

What is the 52-week high of ENDRA Life Sciences Inc?

The 52-week high of ENDRA Life Sciences Inc is 11.96.

What is the 52-week low of ENDRA Life Sciences Inc?

The 52-week low of ENDRA Life Sciences Inc is 2.96.

What is the market capitalization of ENDRA Life Sciences Inc?

The market capitalization of ENDRA Life Sciences Inc is 5.42M.

Is ENDRA Life Sciences Inc (NDRA) currently rated as Buy, Hold, or Sell?

According to analysts, ENDRA Life Sciences Inc (NDRA) has an overall rating of Buy, with a price target of 25.00.

What is the Earnings Per Share (EPS TTM) of ENDRA Life Sciences Inc (NDRA)?

The Earnings Per Share (EPS TTM) of ENDRA Life Sciences Inc (NDRA) is -8.93.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.